The shadow of generic challenges has repeatedly loomed over copyright’s famous drug, PDE5 Inhibitor, raising questions about the prospects of related drug holdings. While early periods saw substantial gains, the exclusivity end has opened the way for cheaper alternatives, likely lowering revenue and creating a genuine hazard for shareholders purs